Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.86 |
| ▸ | ADORA2B | P29275 | 12/20 | 0.86 |
| ▸ | PDE2A | O00408 | 2/20 | 0.76 |
| ▸ | PDE1A | P54750 | 2/20 | 0.76 |
| ▸ | PDE1B | Q01064 | 2/20 | 0.76 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.76 |
| ▸ | PDE4A | P27815 | 13/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.72 |
| ▸ | CFTR | P13569 | 2/20 | 0.72 |
| ▸ | PDE5A | O76074 | 1/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.72 |
| ▸ | SCN1A | P35498 | 1/20 | 0.72 |
| ▸ | PDE6C | P51160 | 1/20 | 0.72 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10339736 | 0.89 | ADORA2A (0.74) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| SCHEMBL515564 | 0.88 | ADORA2A (1.00) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL10579248 | 0.86 | ADORA2B (1.00) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| SCHEMBL4623650 | 0.85 | ADORA2B (0.80) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| Isobutylmethylxanthine SCHEMBL50315 | 0.84 | PDE4A (1.00) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| Isobutylmethylxanthine SCHEMBL28814716 | 0.84 | PDE4A (1.00) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| SCHEMBL9430122 | 0.84 | ADORA2B (0.85) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| SCHEMBL11073850 | 0.84 | ADORA2B (0.78) | ADORA2AADORA2BPDE2APDE1APDE1B | |
| SCHEMBL4623455 | 0.84 | PDE4A (1.00) | ADORA2AADORA2BPDE4APDE4BPDE4C | |
| SCHEMBL7608518 | 0.83 | ADORA2B (0.72) | ADORA2AADORA2BPDE2APDE1APDE1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | claimed |
| EP-3217984-B1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| EP-3217985-B1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | claimed |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SELABTEC SCIENCES, SL (ES) | 2017-11-02 | — | — | US | claimed |
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | INSTITUT UNIV. DE CIENCIA I TECNOLOGIA, S.A. (ES) | 2017-10-26 | — | — | US | claimed |
| EP-3217985-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| EP-3217984-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| WO-2016075285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| WO-2016075288-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | UNIVERSITAT DE VALÈNCIA (ES) | 2016-05-19 | — | — | WO | claimed |
| EP-3020403-A1 | Compounds for the treatment of myotonic dystrophy | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| EP-3020404-A1 | Caffeine for the treatment of myotonic dystrophy type 1 and type 2 | Universitat de Valéncia (ES) | 2016-05-18 | — | — | EP | claimed |
| US-20050148067-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-07-07 | — | — | US | claimed |
| US-6855817-B2 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2005-02-15 | — | — | US | claimed |
| EP-1305328-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | Lyles, Mark B. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | claimed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | claimed |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | UNIVERSITAT DE VALENCIA (ES) | 2019-03-12 | — | — | US | disclosed |
| EP-3217985-B1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | UNIV VALENCIA (ES) | 2018-09-12 | — | — | EP | disclosed |
| US-20020103350-A1 | Materials and methods for binding nucleic acids to surfaces | LYLES MARK B (US) | 2002-08-01 | — | — | US | disclosed |
| WO-2002008237-A2 | MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES | LYLES MARK B (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170304309-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | SMN1; SMN2, TDP2, MTPN | ADORA2A 374/4885ADORA2B 972/4885PDE2A 330/4885 |
| US-20170312285-A1 | COMPOUNDS FOR THE TREATMENT OF MYOTONIC DYSTROPHY | SMN1; SMN2, CPT1B, MTPN | ADORA2A 775/4885ADORA2B 1199/4885PDE2A 304/4885 |
| US-10226467-B2 | Compounds for the treatment of myotonic dystrophy | SMN1; SMN2, CPT1B, MTPN | ADORA2A 775/4885ADORA2B 1199/4885PDE2A 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.